<p>Nexgel Inc. has announced a corporate reorganization involving the spin-off of its drug delivery program into a new entity, NexGelRx. Under the terms of the deal, Nexgel shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx, up to $8 million of capital investment in the spin-off, and Nexgel will receive a 5% global royalty in perpetuity on products sold using its drug delivery technology. Nexgel will also remain the exclusive manufacturer of hydrogel for NexGelRx, which will focus on developing and commercializing prescription drug delivery solutions using Nexgel’s proprietary hydrogel technology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexgel Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600457-en) on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

NXGL

<p>Nexgel Spins Off Drug Delivery Unit into NexGelRx</p>